This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omnicell (OMCL) Looks Good: Stock Adds 5% in Session
by Zacks Equity Research
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Senseonics Holdings (SENS) Surges: Stock Moves 5.2% Higher
by Zacks Equity Research
Senseonics Holdings (SENS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks
by Nalak Das
Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).
Top Ranked Momentum Stocks to Buy for November 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 17th
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
Strength Seen in Fulgent Genetics (FLGT): Stock Soars 11.6%
by Zacks Equity Research
Fulgent Genetics (FLGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
5 Stocks to Buy as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Earnings Estimates Moving Higher for FULGENT GENETIC (FLGT): Time to Buy?
by Zacks Equity Research
FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 1600.00% and 18.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 0.00% and 0.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will FULGENT GENETIC (FLGT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.
5 Top-Ranked Stocks Beating the Market at Midway Q1
by Sweta Killa
Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.
Zacks.com featured highlights include: AQN, IDN, FLGT and SMED
by Zacks Equity Research
Zacks.com featured highlights include: AQN, IDN, FLGT and SMED
4 Breakout Stocks for Explosive Returns
by Nitish Marwah
Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the scope of superlative returns.
Is FULGENT GENETIC (FLGT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (FLGT) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
5 Stocks to Soar in 2020 After Solid Gains in 2019
by Zacks Equity Research
U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.
The Zacks Analyst Blog Highlights: Fulgent Genetics, Teekay Tankers, Ultra Clean, Boot Barn and Sonic Automotive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Fulgent Genetics, Teekay Tankers, Ultra Clean, Boot Barn and Sonic Automotive
2019 Hits a Purple Patch So Far: Check the Movers & Shakers
by Zacks Equity Research
Buy these five bets that reap solid returns from the Wall Street's rally in 2019 and are poised to yield high in the coming year.
Zacks.com featured highlights include: Brinker International, Sonic Automotive, Fulgent Genetics, Hewlett Packard and Regeneron Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Brinker International, Sonic Automotive, Fulgent Genetics, Hewlett Packard and Regeneron Pharmaceuticals
Buy These 5 Top-Ranked Stocks With Upgraded Broker Ratings
by Swayta Shah
By following broker rating upgrades, an investor can easily find attractive stocks.
FULGENT GENETIC (FLGT) Is Up 68.12% in One Week: What You Should Know
by Zacks Equity Research
Does FULGENT GENETIC (FLGT) have what it takes to be a top stock pick for momentum investors? Let's find out.